MiNK Therapeutics
INKTINKT · Stock Price
Historical price data
Overview
MiNK Therapeutics is advancing a first-in-class, allogeneic iNKT cell therapy platform with the mission to deliver effective, readily available 'living medicines' for oncology and inflammatory diseases. The company has demonstrated initial clinical proof-of-concept, having treated over 70 patients across its programs in solid tumors and ARDS, and is leveraging the inherent safety and versatility of iNKT cells to build a pipeline of off-the-shelf products. Its strategy focuses on validating its lead assets, expanding into new indications through strategic combinations, and pioneering next-generation engineered iNKT cells to enhance targeting and persistence.
Technology Platform
Proprietary platform for the expansion, engineering, and cryopreservation of allogeneic invariant natural killer T (iNKT) cells, leveraging their dual-mechanism biology and inherent low risk of graft-versus-host disease for off-the-shelf therapy development.
Pipeline
3| Drug | Indication | Stage | Watch |
|---|---|---|---|
| agenT-797 + Approved ICIs | Tumor, Solid | Phase 1 | |
| agenT-797 | Relapsed/Refractory Multiple Myeloma | Phase 1 | |
| agenT-797 | Respiratory Distress Syndrome, Adult | Phase 1 |
Opportunities
Risk Factors
Competitive Landscape
MiNK competes with autologous CAR-T leaders in hematology and a crowded field of allogeneic cell therapy companies using αβ T, NK, or γδ T cells. Its key differentiator is the unique biology of iNKT cells, which offer a dual mechanism of action and a naturally low risk of graft-versus-host disease without requiring gene editing, potentially simplifying manufacturing and improving safety.
